Q00993
PR
Gene name |
Axl (Ark, Ufo) |
Protein name |
Tyrosine-protein kinase receptor UFO |
Names |
Adhesion-related kinase |
Species |
Mus musculus (Mouse) |
KEGG Pathway |
mmu:26362 |
EC number |
2.7.10.1: Protein-tyrosine kinases |
Protein Class |
|
Descriptions
(Annotation based on sequence homology with Q12866)
Tyrosine-protein kinase Mer (MerTK, Mer) is a transmembrane tyrosine receptor kinase with extracellular immunoglobulin and fibronectin-like domains that recognize ligands such as growth arrest specific 6 (Gas6) and protein S. Ligand-binding leads to autophosphorylation of the tyrosine in the activation loop (Tyr749, Tyr753 and Tyr754) and then results in the activation of downstream enzymes (PI3K, MAPK, GTPase).
Autoinhibitory domains (AIDs)
Target domain |
|
Relief mechanism |
|
Assay |
cis-regPred |
Accessory elements
683-708 (Activation loop from InterPro)
Target domain |
530-801 (Protein kinase domain) |
Relief mechanism |
|
Assay |
|
Autoinhibited structure
Activated structure
1 structures for Q00993
| Entry ID | Method | Resolution | Chain | Position | Source |
|---|---|---|---|---|---|
| AF-Q00993-F1 | Predicted | AlphaFoldDB |
38 variants for Q00993
| Variant ID(s) | Position | Change | Description | Diseaes Association | Provenance |
|---|---|---|---|---|---|
| rs3388883111 | 4 | V>I | No | EVA | |
| rs3388873581 | 12 | L>M | No | EVA | |
| rs215057117 | 20 | H>P | No | EVA | |
| rs3388877443 | 57 | E>K | No | EVA | |
| rs3388883100 | 90 | W>R | No | EVA | |
| rs3397750712 | 102 | Q>H | No | EVA | |
| rs3388891331 | 105 | D>V | No | EVA | |
| rs3388892209 | 108 | E>K | No | EVA | |
| rs3388864604 | 113 | V>M | No | EVA | |
| rs3388886250 | 127 | V>G | No | EVA | |
| rs247094131 | 175 | A>V | No | EVA | |
| rs223800804 | 218 | L>I | No | EVA | |
| rs257321301 | 223 | H>Y | No | EVA | |
| rs3388877383 | 230 | R>K | No | EVA | |
| rs1133911519 | 262 | G>E | No | EVA | |
| rs3388873517 | 277 | L>P | No | EVA | |
| rs3388873595 | 284 | P>S | No | EVA | |
| rs3388895950 | 287 | Q>L | No | EVA | |
| rs3388892216 | 297 | T>I | No | EVA | |
| rs3388891360 | 306 | S>C | No | EVA | |
| rs3397739719 | 316 | H>P | No | EVA | |
| rs3388886207 | 384 | T>I | No | EVA | |
| rs3388892550 | 388 | R>Q | No | EVA | |
| rs3388886087 | 390 | D>N | No | EVA | |
| rs3388873549 | 400 | V>G | No | EVA | |
| rs3388888579 | 501 | R>W | No | EVA | |
| rs3397848664 | 620 | G>R | No | EVA | |
| rs3388864596 | 681 | C>R | No | EVA | |
| rs3388877406 | 696 | Y>C | No | EVA | |
| rs3388889938 | 717 | D>G | No | EVA | |
| rs3388892213 | 719 | V>D | No | EVA | |
| rs3388849778 | 754 | D>V | No | EVA | |
| rs237691755 | 757 | R>H | No | EVA | |
| rs3388889914 | 827 | P>S | No | EVA | |
| rs3388883115 | 835 | D>E | No | EVA | |
| rs238862367 | 852 | A>V | No | EVA | |
| rs3388889853 | 869 | G>E | No | EVA | |
| rs3388881281 | 880 | A>V | No | EVA |
No associated diseases with Q00993
11 regional properties for Q00993
| Type | Name | Position | InterPro Accession |
|---|---|---|---|
| domain | Protein kinase domain | 530 - 801 | IPR000719 |
| domain | Serine-threonine/tyrosine-protein kinase, catalytic domain | 531 - 797 | IPR001245 |
| domain | Immunoglobulin subtype | 35 - 124 | IPR003599-1 |
| domain | Immunoglobulin subtype | 139 - 218 | IPR003599-2 |
| domain | Fibronectin type III | 219 - 325 | IPR003961-1 |
| domain | Fibronectin type III | 328 - 422 | IPR003961-2 |
| domain | Immunoglobulin-like domain | 30 - 122 | IPR007110-1 |
| domain | Immunoglobulin-like domain | 133 - 216 | IPR007110-2 |
| active_site | Tyrosine-protein kinase, active site | 662 - 674 | IPR008266 |
| binding_site | Protein kinase, ATP binding site | 536 - 561 | IPR017441 |
| domain | Tyrosine-protein kinase, catalytic domain | 530 - 797 | IPR020635 |
Functions
| Description | ||
|---|---|---|
| EC Number | 2.7.10.1 | Protein-tyrosine kinases |
| Subcellular Localization |
|
|
| PANTHER Family | ||
| PANTHER Subfamily | ||
| PANTHER Protein Class | ||
| PANTHER Pathway Category | No pathway information available | |
8 GO annotations of cellular component
| Name | Definition |
|---|---|
| actin cytoskeleton | The part of the cytoskeleton (the internal framework of a cell) composed of actin and associated proteins. Includes actin cytoskeleton-associated complexes. |
| cell surface | The external part of the cell wall and/or plasma membrane. |
| extracellular space | That part of a multicellular organism outside the cells proper, usually taken to be outside the plasma membranes, and occupied by fluid. |
| host cell surface | The external part of the host cell wall and/or host plasma membrane. |
| integral component of plasma membrane | The component of the plasma membrane consisting of the gene products and protein complexes having at least some part of their peptide sequence embedded in the hydrophobic region of the membrane. |
| intracellular membrane-bounded organelle | Organized structure of distinctive morphology and function, bounded by a single or double lipid bilayer membrane and occurring within the cell. Includes the nucleus, mitochondria, plastids, vacuoles, and vesicles. Excludes the plasma membrane. |
| plasma membrane | The membrane surrounding a cell that separates the cell from its external environment. It consists of a phospholipid bilayer and associated proteins. |
| receptor complex | Any protein complex that undergoes combination with a hormone, neurotransmitter, drug or intracellular messenger to initiate a change in cell function. |
7 GO annotations of molecular function
| Name | Definition |
|---|---|
| ATP binding | Binding to ATP, adenosine 5'-triphosphate, a universally important coenzyme and enzyme regulator. |
| myosin heavy chain binding | Binding to a heavy chain of a myosin complex. |
| phosphatidylinositol 3-kinase binding | Binding to a phosphatidylinositol 3-kinase, any enzyme that catalyzes the addition of a phosphate group to an inositol lipid at the 3' position of the inositol ring. |
| phosphatidylserine binding | Binding to phosphatidylserine, a class of glycophospholipids in which a phosphatidyl group is esterified to the hydroxyl group of L-serine. |
| protein tyrosine kinase activity | Catalysis of the reaction: ATP + a protein tyrosine = ADP + protein tyrosine phosphate. |
| transmembrane receptor protein tyrosine kinase activity | Combining with a signal and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity by catalysis of the reaction: ATP + a protein-L-tyrosine = ADP + a protein-L-tyrosine phosphate. |
| virus receptor activity | Combining with a virus component and mediating entry of the virus into the cell. |
49 GO annotations of biological process
| Name | Definition |
|---|---|
| animal organ regeneration | The regrowth of a lost or destroyed animal organ. |
| apoptotic cell clearance | The recognition and removal of an apoptotic cell by a neighboring cell or by a phagocyte. |
| apoptotic process | A programmed cell death process which begins when a cell receives an internal (e.g. DNA damage) or external signal (e.g. an extracellular death ligand), and proceeds through a series of biochemical events (signaling pathway phase) which trigger an execution phase. The execution phase is the last step of an apoptotic process, and is typically characterized by rounding-up of the cell, retraction of pseudopodes, reduction of cellular volume (pyknosis), chromatin condensation, nuclear fragmentation (karyorrhexis), plasma membrane blebbing and fragmentation of the cell into apoptotic bodies. When the execution phase is completed, the cell has died. |
| blood vessel remodeling | The reorganization or renovation of existing blood vessels. |
| cell differentiation | The process in which relatively unspecialized cells, e.g. embryonic or regenerative cells, acquire specialized structural and/or functional features that characterize the cells, tissues, or organs of the mature organism or some other relatively stable phase of the organism's life history. Differentiation includes the processes involved in commitment of a cell to a specific fate and its subsequent development to the mature state. |
| cell maturation | A developmental process, independent of morphogenetic (shape) change, that is required for a cell to attain its fully functional state. |
| cell migration | The controlled self-propelled movement of a cell from one site to a destination guided by molecular cues. Cell migration is a central process in the development and maintenance of multicellular organisms. |
| cellular response to extracellular stimulus | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an extracellular stimulus. |
| cellular response to hydrogen peroxide | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a hydrogen peroxide (H2O2) stimulus. |
| cellular response to interferon-alpha | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an interferon-alpha stimulus. Interferon-alpha is a type I interferon. |
| cellular response to lipopolysaccharide | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a lipopolysaccharide stimulus; lipopolysaccharide is a major component of the cell wall of gram-negative bacteria. |
| dendritic cell differentiation | The process in which a precursor cell type acquires the specialized features of a dendritic cell. A dendritic cell is a leukocyte of dendritic lineage specialized in the uptake, processing, and transport of antigens to lymph nodes for the purpose of stimulating an immune response via T cell activation. |
| enzyme-linked receptor protein signaling pathway | The series of molecular signals initiated by an extracellular ligand binding to a receptor on the surface of the target cell, where the receptor possesses catalytic activity or is closely associated with an enzyme such as a protein kinase, and ending with the regulation of a downstream cellular process, e.g. transcription. |
| erythrocyte homeostasis | Any process of regulating the production and elimination of erythrocytes within an organism. |
| establishment of localization in cell | Any process, occuring in a cell, that localizes a substance or cellular component. This may occur via movement, tethering or selective degradation. |
| forebrain cell migration | The orderly movement of a cell from one site to another at least one of which is located in the forebrain. |
| inflammatory response | The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. |
| innate immune response | Innate immune responses are defense responses mediated by germline encoded components that directly recognize components of potential pathogens. |
| lymphocyte activation | A change in morphology and behavior of a lymphocyte resulting from exposure to a specific antigen, mitogen, cytokine, chemokine, cellular ligand, or soluble factor. |
| natural killer cell differentiation | The process in which a relatively unspecialized cell acquires the specialized features of a natural killer cell. |
| negative regulation of apoptotic process | Any process that stops, prevents, or reduces the frequency, rate or extent of cell death by apoptotic process. |
| negative regulation of cytokine production | Any process that stops, prevents, or reduces the rate of production of a cytokine. |
| negative regulation of dendritic cell apoptotic process | Any process that stops, prevents or reduces the frequency, rate or extent of dendritic cell apoptotic process. |
| negative regulation of interferon-gamma production | Any process that stops, prevents, or reduces the frequency, rate, or extent of interferon-gamma production. Interferon-gamma is also known as type II interferon. |
| negative regulation of lymphocyte activation | Any process that stops, prevents, or reduces the frequency, rate or extent of lymphocyte activation. |
| negative regulation of macrophage cytokine production | Any process that decreases the rate, frequency or extent of macrophage cytokine production. Macrophage cytokine production is the appearance of a chemokine due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels. |
| negative regulation of neuron apoptotic process | Any process that stops, prevents, or reduces the frequency, rate or extent of cell death by apoptotic process in neurons. |
| negative regulation of tumor necrosis factor production | Any process that stops, prevents, or reduces the frequency, rate, or extent of tumor necrosis factor production. |
| nervous system development | The process whose specific outcome is the progression of nervous tissue over time, from its formation to its mature state. |
| neuron apoptotic process | Any apoptotic process in a neuron, the basic cellular unit of nervous tissue. Each neuron consists of a body, an axon, and dendrites. Their purpose is to receive, conduct, and transmit impulses in the nervous system. |
| neuron migration | The characteristic movement of an immature neuron from germinal zones to specific positions where they will reside as they mature. |
| neutrophil clearance | The selective elimination of senescent neutrophils from the body by autoregulatory mechanisms. |
| ovulation cycle | The type of sexual cycle seen in females, often with physiologic changes in the endometrium that recur at regular intervals during the reproductive years. |
| phagocytosis | A vesicle-mediated transport process that results in the engulfment of external particulate material by phagocytes and their delivery to the lysosome. The particles are initially contained within phagocytic vacuoles (phagosomes), which then fuse with primary lysosomes to effect digestion of the particles. |
| platelet activation | A series of progressive, overlapping events triggered by exposure of the platelets to subendothelial tissue. These events include shape change, adhesiveness, aggregation, and release reactions. When carried through to completion, these events lead to the formation of a stable hemostatic plug. |
| positive regulation of cytokine-mediated signaling pathway | Any process that activates or increases the frequency, rate or extent of a cytokine mediated signaling pathway. |
| positive regulation of kinase activity | Any process that activates or increases the frequency, rate or extent of kinase activity, the catalysis of the transfer of a phosphate group, usually from ATP, to a substrate molecule. |
| positive regulation of natural killer cell differentiation | Any process that activates or increases the frequency, rate or extent of natural killer cell differentiation. |
| positive regulation of pinocytosis | Any process that activates, maintains or increases the rate of pinocytosis. Pinocytosis is the process in which cells take in liquid material from their external environment; literally 'cell drinking'. Liquid is enclosed in vesicles, formed by invagination of the plasma membrane. These vesicles then move into the cell and pass their contents to endosomes. |
| positive regulation of protein kinase B signaling | Any process that activates or increases the frequency, rate or extent of protein kinase B signaling, a series of reactions mediated by the intracellular serine/threonine kinase protein kinase B. |
| positive regulation of viral life cycle | Any process that activates or increases the frequency, rate or extent of viral life cycle. |
| protein kinase B signaling | A series of reactions, mediated by the intracellular serine/threonine kinase protein kinase B (also called AKT), which occurs as a result of a single trigger reaction or compound. |
| response to axon injury | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an axon injury stimulus. |
| secretion by cell | The controlled release of a substance by a cell. |
| spermatogenesis | The developmental process by which male germ line stem cells self renew or give rise to successive cell types resulting in the development of a spermatozoa. |
| substrate adhesion-dependent cell spreading | The morphogenetic process that results in flattening of a cell as a consequence of its adhesion to a substrate. |
| transmembrane receptor protein tyrosine kinase signaling pathway | The series of molecular signals initiated by an extracellular ligand binding to a receptor on the surface of the target cell where the receptor possesses tyrosine kinase activity, and ending with the regulation of a downstream cellular process, e.g. transcription. |
| vagina development | The reproductive developmental process whose specific outcome is the progression of the vagina over time, from its formation to the mature structure. |
| viral entry into host cell | The process that occurs after viral attachment by which a virus, or viral nucleic acid, breaches the plasma membrane or cell envelope and enters the host cell. The process ends when the viral nucleic acid is released into the host cell cytoplasm. |
66 homologous proteins in AiPD
| UniProt AC | Gene Name | Protein Name | Species | Evidence Code |
|---|---|---|---|---|
| P08581 | MET | Hepatocyte growth factor receptor | Homo sapiens (Human) | EV |
| Q04912 | MST1R | Macrophage-stimulating protein receptor | Homo sapiens (Human) | EV |
| Q12866 | MERTK | Tyrosine-protein kinase Mer | Homo sapiens (Human) | EV |
| Q06418 | TYRO3 | Tyrosine-protein kinase receptor TYRO3 | Homo sapiens (Human) | SS |
| P30530 | AXL | Tyrosine-protein kinase receptor UFO | Homo sapiens (Human) | PR |
| P34925 | RYK | Tyrosine-protein kinase RYK | Homo sapiens (Human) | PR |
| Q60805 | Mertk | Tyrosine-protein kinase Mer | Mus musculus (Mouse) | SS |
| Q03145 | Epha2 | Ephrin type-A receptor 2 | Mus musculus (Mouse) | PR |
| Q9Z138 | Ror2 | Tyrosine-protein kinase transmembrane receptor ROR2 | Mus musculus (Mouse) | SS |
| Q9WTL4 | Insrr | Insulin receptor-related protein | Mus musculus (Mouse) | SS |
| Q3UFB7 | Ntrk1 | High affinity nerve growth factor receptor | Mus musculus (Mouse) | SS |
| Q9Z139 | Ror1 | Inactive tyrosine-protein kinase transmembrane receptor ROR1 | Mus musculus (Mouse) | PR |
| Q60629 | Epha5 | Ephrin type-A receptor 5 | Mus musculus (Mouse) | SS |
| Q60750 | Epha1 | Ephrin type-A receptor 1 | Mus musculus (Mouse) | SS |
| P97793 | Alk | ALK tyrosine kinase receptor | Mus musculus (Mouse) | SS |
| P15208 | Insr | Insulin receptor | Mus musculus (Mouse) | SS |
| P54761 | Ephb4 | Ephrin type-B receptor 4 | Mus musculus (Mouse) | PR |
| P35546 | Ret | Proto-oncogene tyrosine-protein kinase receptor Ret | Mus musculus (Mouse) | SS |
| Q61006 | Musk | Muscle, skeletal receptor tyrosine-protein kinase | Mus musculus (Mouse) | SS |
| Q62371 | Ddr2 | Discoidin domain-containing receptor 2 | Mus musculus (Mouse) | SS |
| Q03146 | Ddr1 | Epithelial discoidin domain-containing receptor 1 | Mus musculus (Mouse) | SS |
| P15209 | Ntrk2 | BDNF/NT-3 growth factors receptor | Mus musculus (Mouse) | SS |
| Q6VNS1 | Ntrk3 | NT-3 growth factor receptor | Mus musculus (Mouse) | SS |
| P35917 | Flt4 | Vascular endothelial growth factor receptor 3 | Mus musculus (Mouse) | SS |
| P35969 | Flt1 | Vascular endothelial growth factor receptor 1 | Mus musculus (Mouse) | SS |
| P35918 | Kdr | Vascular endothelial growth factor receptor 2 | Mus musculus (Mouse) | PR |
| Q60751 | Igf1r | Insulin-like growth factor 1 receptor | Mus musculus (Mouse) | SS |
| P16092 | Fgfr1 | Fibroblast growth factor receptor 1 | Mus musculus (Mouse) | SS |
| P21803 | Fgfr2 | Fibroblast growth factor receptor 2 | Mus musculus (Mouse) | SS |
| Q03142 | Fgfr4 | Fibroblast growth factor receptor 4 | Mus musculus (Mouse) | PR |
| Q62190 | Mst1r | Macrophage-stimulating protein receptor | Mus musculus (Mouse) | SS |
| P55144 | Tyro3 | Tyrosine-protein kinase receptor TYRO3 | Mus musculus (Mouse) | SS |
| P70424 | Erbb2 | Receptor tyrosine-protein kinase erbB-2 | Mus musculus (Mouse) | SS |
| Q61527 | Erbb4 | Receptor tyrosine-protein kinase erbB-4 | Mus musculus (Mouse) | SS |
| Q61526 | Erbb3 | Receptor tyrosine-protein kinase erbB-3 | Mus musculus (Mouse) | SS |
| Q01279 | Egfr | Epidermal growth factor receptor | Mus musculus (Mouse) | SS |
| Q01887 | Ryk | Tyrosine-protein kinase RYK | Mus musculus (Mouse) | PR |
| Q02858 | Tek | Angiopoietin-1 receptor | Mus musculus (Mouse) | SS |
| Q06806 | Tie1 | Tyrosine-protein kinase receptor Tie-1 | Mus musculus (Mouse) | SS |
| P05532 | Kit | Mast/stem cell growth factor receptor Kit | Mus musculus (Mouse) | PR |
| P05622 | Pdgfrb | Platelet-derived growth factor receptor beta | Mus musculus (Mouse) | SS |
| P09581 | Csf1r | Macrophage colony-stimulating factor 1 receptor | Mus musculus (Mouse) | SS |
| P26618 | Pdgfra | Platelet-derived growth factor receptor alpha | Mus musculus (Mouse) | SS |
| Q00342 | Flt3 | Receptor-type tyrosine-protein kinase FLT3 | Mus musculus (Mouse) | SS |
| P16056 | Met | Hepatocyte growth factor receptor | Mus musculus (Mouse) | PR |
| Q61851 | Fgfr3 | Fibroblast growth factor receptor 3 | Mus musculus (Mouse) | PR |
| Q2QLE0 | MET | Hepatocyte growth factor receptor | Sus scrofa (Pig) | PR |
| P57097 | Mertk | Tyrosine-protein kinase Mer | Rattus norvegicus (Rat) | SS |
| H2KZU7 | svh-2 | Tyrosine-protein kinase receptor svh-2 | Caenorhabditis elegans | SS |
| P43298 | TMK1 | Receptor protein kinase TMK1 | Arabidopsis thaliana (Mouse-ear cress) | PR |
| C0LGI2 | At1g67720 | Probable LRR receptor-like serine/threonine-protein kinase At1g67720 | Arabidopsis thaliana (Mouse-ear cress) | PR |
| Q8LPS5 | SERK5 | Somatic embryogenesis receptor kinase 5 | Arabidopsis thaliana (Mouse-ear cress) | PR |
| Q9LRP3 | At3g17420 | Probable receptor-like protein kinase At3g17420 | Arabidopsis thaliana (Mouse-ear cress) | PR |
| Q94C77 | At4g34220 | Receptor protein kinase-like protein At4g34220 | Arabidopsis thaliana (Mouse-ear cress) | PR |
| O64556 | At2g19230 | Putative leucine-rich repeat receptor-like serine/threonine-protein kinase At2g19230 | Arabidopsis thaliana (Mouse-ear cress) | PR |
| Q6XAT2 | ERL2 | LRR receptor-like serine/threonine-protein kinase ERL2 | Arabidopsis thaliana (Mouse-ear cress) | PR |
| Q3E991 | PRK6 | Pollen receptor-like kinase 6 | Arabidopsis thaliana (Mouse-ear cress) | PR |
| Q94AG2 | SERK1 | Somatic embryogenesis receptor kinase 1 | Arabidopsis thaliana (Mouse-ear cress) | PR |
| Q9XIC7 | SERK2 | Somatic embryogenesis receptor kinase 2 | Arabidopsis thaliana (Mouse-ear cress) | PR |
| C0LGJ1 | At1g74360 | Probable LRR receptor-like serine/threonine-protein kinase At1g74360 | Arabidopsis thaliana (Mouse-ear cress) | PR |
| Q93ZS4 | NIK3 | Protein NSP-INTERACTING KINASE 3 | Arabidopsis thaliana (Mouse-ear cress) | PR |
| C0LGQ4 | MDIS2 | Protein MALE DISCOVERER 2 | Arabidopsis thaliana (Mouse-ear cress) | PR |
| Q0WR59 | At5g10020 | Probable inactive receptor kinase At5g10020 | Arabidopsis thaliana (Mouse-ear cress) | PR |
| C0LGX1 | At5g65240 | Probable LRR receptor-like serine/threonine-protein kinase At5g65240 | Arabidopsis thaliana (Mouse-ear cress) | PR |
| Q9LFG1 | At3g53590 | Putative leucine-rich repeat receptor-like serine/threonine-protein kinase At3g53590 | Arabidopsis thaliana (Mouse-ear cress) | PR |
| Q9FXF2 | RKF1 | Probable LRR receptor-like serine/threonine-protein kinase RFK1 | Arabidopsis thaliana (Mouse-ear cress) | PR |
| 10 | 20 | 30 | 40 | 50 | 60 |
| MGRVPLAWWL | ALCCWGCAAH | KDTQTEAGSP | FVGNPGNITG | ARGLTGTLRC | ELQVQGEPPE |
| 70 | 80 | 90 | 100 | 110 | 120 |
| VVWLRDGQIL | ELADNTQTQV | PLGEDWQDEW | KVVSQLRISA | LQLSDAGEYQ | CMVHLEGRTF |
| 130 | 140 | 150 | 160 | 170 | 180 |
| VSQPGFVGLE | GLPYFLEEPE | DKAVPANTPF | NLSCQAQGPP | EPVTLLWLQD | AVPLAPVTGH |
| 190 | 200 | 210 | 220 | 230 | 240 |
| SSQHSLQTPG | LNKTSSFSCE | AHNAKGVTTS | RTATITVLPQ | RPHHLHVVSR | QPTELEVAWT |
| 250 | 260 | 270 | 280 | 290 | 300 |
| PGLSGIYPLT | HCNLQAVLSD | DGVGIWLGKS | DPPEDPLTLQ | VSVPPHQLRL | EKLLPHTPYH |
| 310 | 320 | 330 | 340 | 350 | 360 |
| IRISCSSSQG | PSPWTHWLPV | ETTEGVPLGP | PENVSAMRNG | SQVLVRWQEP | RVPLQGTLLG |
| 370 | 380 | 390 | 400 | 410 | 420 |
| YRLAYRGQDT | PEVLMDIGLT | REVTLELRGD | RPVANLTVSV | TAYTSAGDGP | WSLPVPLEPW |
| 430 | 440 | 450 | 460 | 470 | 480 |
| RPGQGQPLHH | LVSEPPPRAF | SWPWWYVLLG | ALVAAACVLI | LALFLVHRRK | KETRYGEVFE |
| 490 | 500 | 510 | 520 | 530 | 540 |
| PTVERGELVV | RYRVRKSYSR | RTTEATLNSL | GISEELKEKL | RDVMVDRHKV | ALGKTLGEGE |
| 550 | 560 | 570 | 580 | 590 | 600 |
| FGAVMEGQLN | QDDSILKVAV | KTMKIAICTR | SELEDFLSEA | VCMKEFDHPN | VMRLIGVCFQ |
| 610 | 620 | 630 | 640 | 650 | 660 |
| GSDREGFPEP | VVILPFMKHG | DLHSFLLYSR | LGDQPVFLPT | QMLVKFMADI | ASGMEYLSTK |
| 670 | 680 | 690 | 700 | 710 | 720 |
| RFIHRDLAAR | NCMLNENMSV | CVADFGLSKK | IYNGDYYRQG | RIAKMPVKWI | AIESLADRVY |
| 730 | 740 | 750 | 760 | 770 | 780 |
| TSKSDVWSFG | VTMWEIATRG | QTPYPGVENS | EIYDYLRQGN | RLKQPVDCLD | GLYALMSRCW |
| 790 | 800 | 810 | 820 | 830 | 840 |
| ELNPRDRPSF | AELREDLENT | LKALPPAQEP | DEILYVNMDE | GGSHLEPRGA | AGGADPPTQP |
| 850 | 860 | 870 | 880 | ||
| DPKDSCSCLT | AADVHSAGRY | VLCPSTAPGP | TLSADRGCPA | PPGQEDGA |